ArticleCardiology and therapy2026
Trimetazidine's Anti-ischemic Effectiveness in Patients with Stable Angina with Prior Myocardial Infarction Evaluated via Stress Echocardiography with Speckle Tracking: METHOD study.
Article in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05210465 (Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStress-test echocardiography with speckle tracking modality (STM) is sensitive to detect myocardial ischemia. Data on trimetazidine (TMZ) therapy's effectiveness on myocardial ischemia and contractile function using STM is limited. This study aimed to assess the anti-ischemic effectiveness of trimetazidine 80 mg once daily (TMZ OD) in patients with symptomatic stable coronary artery disease (CAD) with a history of myocardial infarction (MI), in real-world practice.
methodsThe METHOD study (NCT05210465) was a 6-month observational study evaluating TMZ OD's anti-ischemic and antianginal effectiveness in CAD patients with MI history using stress echocardiography with dobutamine and STM. Adult outpatients starting TMZ OD alongside standard antianginal therapy were included. The primary outcome was the mean change in left ventricular global longitudinal strain (LV GLS) after 6 months. Secondary outcomes were changes in regional peak systolic deformation (RPSD) and global post-systolic index, along with traditional antianginal effectiveness indicators and quality of life (QoL) using the EQ-5D-5L questionnaire.
resultsThirty-six patients were included. TMZ OD significantly improved LV GLS by 2% (95% CI - 2.6 to - 1.5, p < 0.001). RPSD significant improvements were observed in 12/17 LV segments, ranging from - 2.6% to - 0.5%. Angina frequency and short-acting nitrate use decreased from 1.0 (1.4) to 0.1 (0.4) attacks per week and from 0.5 (1.0) to 0.1 (0.3) times per week, respectively (both p < 0.05). QoL improved significantly in mobility (1.8 [0.9] vs. 1.4 [0.7]), pain (2.0 [0.4] vs. 1.3 [0.5]) and anxiety domains (1.5 [0.7] vs. 1.2 [0.5]), (all p < 0.05). TMZ OD was well tolerated with no reported adverse events.
conclusionsThis real-world study supports TMZ OD role as a valuable adjunct to standard antianginal therapy in outpatients with stable CAD and a history of MI.
trial registrationClinicalTrialsGov: The METHOD (NCT05210465).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.